

**List of positions held by the Executive board and Supervisory board members**

I-The following table lists the other positions held by members of the Executive board for the fiscal year ending December 31, 2016 and for the last five years:

<b>First and last name, nationality and age<sup>(1)</sup></b>	<b>Duration of Term</b>	<b>Position</b>	<b>Other Positions and Appointments held in any other company over the last five years</b>
<b>Mondher Mahjoubi</b> French Age 58	<u>First nomination:</u> Supervisory board of 12/14/16, with effect on 12/30/16  <u>Term expires:</u> Ordinary General Meeting of 2020 to be held to vote on the accounts for the fiscal year ending on 12/31/19	Chairman of the Executive board since December 30, 2016	<u>Positions previously held in unlisted companies:</u> Senior VP “head of oncology TA” at Genentech  <u>Positions previously held in listed companies:</u> Senior VP “head of oncology TA” at AstraZeneca
<b>Hervé Brailly<sup>(1)</sup></b> French Age 55  Innate Pharma 117, Avenue de Luminy 13009 Marseille	<u>First nomination:</u> Supervisory board of June 13, 2005 renewed by the Supervisory board of 06/29/11 then by the Supervisory board of 03/27/14  <u>Term expires :</u> General Meeting of 2017 Meeting to be held to vote on the accounts for the fiscal year ending Dec. 31, 2016	Chairman of the Supervisory board until December 29, 2016	<u>Mandates and positions in unlisted companies:</u> Member of the executive committee and treasurer of EurobioMed; Member of the development council of Marseille Provence Métropole; Member of the Strategy and Prospects committee of Aix Marseille University; Member of the investment committee of SATT Sud-Est; Chairman of Kervrant Biotech SAS.  <u>Mandate in listed companies:</u> Chairman of the Executive board of Innate Pharma (resignation on 12/29/16)  <u>Terminated mandates:</u> Member of the Supervisory board of Inserm Transfert (not renewed in 2014); Elected member of the Chamber of Commerce of Marseille (not renewed in 2012); Member of the board of directors of Platine Pharma Services (not renewed in 2014), Chairman of the Board of directors of Innate Pharma, Inc. (resignation on 12/30/16).

**Ms. Catherine  
Moukheibir(2)**  
**Lebanese**  
**Age 56**

First nomination :  
Supervisory board  
of May 5, 2011  
renewed by the  
Supervisory board  
of 06/29/11 then by  
the Supervisory  
board of 03/27/14

Term expires :  
General Meeting of  
2017 Meeting to be  
held to vote on the  
accounts for the  
fiscal year ending  
Dec. 31, 2016

Member of the  
Executive board  
and Senior  
Finance Advisor  
(resignation on  
December 30,  
2016)

Mandates in listed companies: Member  
of Supervisory board and Audit  
Committee of Cerenis (from 2015);  
Member of Supervisory board and  
Chairman of Audit Committee of  
Zealand Pharma (from 2015); Member  
of Supervisory board and Audit  
Committee of Ablynx (from June 2013)

Mandates in unlisted companies:  
Chairman of the Boar of Directors of  
medDay (since April, 2016);

Terminated mandate: Member of the  
Supervisory board and Chairman of the  
Audit Committee of Octoplus (2012-  
2013); Partner in the consultancy firm  
STJ Advisors (2011-2013); Member of  
the Supervisory board of  
Creabilis (from December 2012 to  
December 2016) and President of the  
Supervisory board (from January, 2015  
to December, 2016),

**Nicolai  
Wagtmann**  
**Danish**  
**Age 53**

First nomination:  
Supervisory board  
of 12/12/13 as a  
replacement for  
Francois Romagné  
Renewed by the  
Supervisory board  
of 03/27/14

Renewed by the  
Supervisory board  
of 12/14/16 with  
effect on 12/30/16

Term expires:  
Ordinary General  
Meeting of 2020  
Meeting to be held  
to vote on the  
accounts for the  
fiscal year ending  
on 12/31/19

Member of the  
Executive board  
and Chief  
Scientific Officer

Position previously held in a listed  
company: VP, head of the  
inflammation biology and member of  
the direction of the biopharmaceutical  
unit research at Novo Nordisk A/S  
(end on the contract in 2013).

<b>Yannis Morel</b> French Age 43	<u>First nomination:</u> Supervisory board of 06/25/15  Renewed by the Supervisory board of 12/14/16 with effect on 12/30/16  <u>Term expires:</u> Ordinary General Meeting of 2020 Meeting to be held to vote on the accounts for the fiscal year ending on 12/31/19	Member of the None Executive board and Business Development
---	---	--

- (1) For the needs of their social mandate, the Executive board members of the Company are domiciled at the Company's registered office.
- (2) Mrs. Moukheibir is bound to the Company with a consultant agreement.

II-The following table lists the other positions held by the members of the Supervisory board for the fiscal year ending December 31, 2016 and for the last five years:

<b>First and last name, nationality age and professional address</b>	<b>Duration of Term</b>	<b>Position</b>	<b>Other Positions and Appointments held in any other company over the last five years</b>
<b>Gilles Brisson</b> French Age 65  Innate Pharma 117, Avenue de Luminy 13009 Marseille	<u>First Appointment:</u> Ordinary General Meeting on 06/26/07  Renewed by the Ordinary General Meetings on 06/23/09, 06/29/11, 06/28/13 and 04/27/15.  <u>Term expires:</u> 2017 Ordinary General Meeting to be held to vote on the accounts for the fiscal year ending on 12/31/16.	Member of the Supervisory board	<u>Mandates and positions in unlisted companies:</u> Chairman of Mutabilis holding SAS; Chairman of the Supervisory board of Ethypharm SA; Member of the Supervisory board of the Carso Group; Chairman of the Board of directors of Mauna Kea Technologies (listed company).
<b>Patrick Langlois,</b> French Age 71  PJJ Conseils 6, Avenue Frederic Le Play 75007 Paris	<u>First Appointment:</u> Ordinary General Meeting on 05/25/10  Renewed by the Ordinary General Meetings on 06/23/09, 06/29/11, 06/28/13 and 04/27/15.  <u>Term expires:</u> 2017 Ordinary General Meeting to be held to vote on the accounts for the fiscal year ending on 12/31/16.	Member of the Supervisory board	<u>Mandates in listed companies:</u> Stallergènes Greer PLC: Independent member of the Board of directors and member of the Compensation committee; Scynexis (US): Director and member of the Compensation and audit committees; Newron (Italy): Director, Chairman of the Audit committee and member of the Compensation committee; Sensorion SA (FR): Chairman of the board and Chairman of the compensation committee.  <u>Terminated mandates:</u> Diaxonhit (France): Director and member of the Audit committee (not renewed in 2014); ONXEO SA: Chairman of the Board of Directors (non renewed in 2016).

<b>First and last name, nationality age and professional address</b>	<b>Duration of Term</b>	<b>Position</b>	<b>Other Positions and Appointments held in any other company over the last five years</b>
<b>Mr. Philippe Pouletty</b> French age 56 Truffle Capital, 5, rue de la Baume 75008 Paris	<u>First Appointment:</u> General Meeting on December 22, 2001. Renewed by the Ordinary General Meetings on June 26, 2007, June 23, 2009, June 29, 2011, June 28, 2013 and April 27, 2015  <u>Resignation:</u> December 14, 2016, with effect on December 30, 2016	Member of the Supervisory board	<u>Positions in listed companies:</u> Chairman of the Board of Directors of Deinove, Director representing Truffle Capital SAS to the boards of Vexim SA, Carmat SA and Theradiag  <u>Positions in unlisted companies:</u> Chairman of the Board of Directors of Abivax S.A, Director representing Truffle Capital SAS on the boards of Pharnex SAS, Biokinesis SAS, Myopowers SA, Diaccurate, Altimune Inc. and Deinobiotics, member of the board of directors and managing director of Truffle Capital SAS, General Manager of Nakostech SARL,  <u>Terminated positions:</u> Honorary President and Director of France Biotech (2012); at BMD SA(2012); mandate as board member not renewed in Targeting Systems Ltd (Royaume-Uni) (2015); Neovacs SA (2014); Splicos SAS (2013); Wittycell SAS (2013). Board member of the <i>l'Association du Centre Chirurgical Marie Lannelongue</i> (2016), board member representing Truffle Capital SAS to the boards of Theraclion SA (2016), Plasmaprime SAS, Carbios SA (2016), Theradiag (2017), Symetis (2016), Myopowers (2016)
<b>Irina Staatz-Granzer</b> German Age 56  Zielstattstrasse 44, D-81379, Munich, Germany	<u>First Appointment:</u> Ordinary General Meeting on 06/23/09  Renewed by the Ordinary General Meetings on 06/29/11, 06/28/13 and 04/27/15  <u>Term expires:</u> 2017 Ordinary General Meeting to be held to vote on the accounts for the fiscal year ending on 12/31/16.	Vice Chairman and member of the Supervisory board	<u>Positions in unlisted companies:</u> Staatz Business Development & Strategy, founder  Blink Therapeutics Ltd: Chairman (2014); Blink Biomedicals SAS: Chairman (2015); PLCD (German Pharma Licensing Club): President.  <u>Terminated position:</u> CEO of U3 Pharma AG

<b>First and last name, nationality age and professional address</b>	<b>Duration of Term</b>	<b>Position</b>	<b>Other Positions and Appointments held in any other company over the last five years</b>
<b>Novo Nordisk A/S,</b> represented by Karsten Munk Knudsen <sup>(1)</sup> Danish Age 44  Novo Allé 2880 Bagsværd Denmark	<u>First Appointment:</u> Ordinary General Meeting on 06/26/07  Renewed by the Ordinary General Meetings on 06/23/09, 06/29/11, 06/28/13 and 04/27/15.  <u>Term expires:</u> 2017 Ordinary General Meeting to be held to vote on the accounts for the fiscal year ending on 12/31/16.	Member of the Supervisory board	None
<b>Michael A. Caligiuri</b> American Age 61  OSU James Cancer Hospital, 300W. 10th Avenue, Suite 519, Columbus, OH43210	<u>First Appointment:</u> Ordinary General Meeting on 06/26/13  Renewed by the Ordinary General Meetings on 04/27/15.  <u>Term expires:</u> 2017 Ordinary General Meeting to be held to vote on the accounts for the fiscal year ending on 12/31/16.	Member of the Supervisory board	<u>Other positions and mandates in  unlisted Company:</u> Member of the Board of Directors of the American Association of Cancer Research (AACR); President of the National Cancer Policy Forum, of the National Institute of Medicine (USA) Member of the Management Committee of Pelotonia; President of the Society for Natural Immunity
<b>Véronique  Chabernaud</b> French Age: 55  Innate Pharma 117, Avenue de Luminy 13009 Marseille	<u>First Appointment:</u> Ordinary General Meeting on April 04/27/15.  <u>Term expires:</u> 2017 Ordinary General Meeting to be held to vote on the accounts for the fiscal year ending on 12/31/16.	Member of the Supervisory board	<u>Other positions and mandates  held in unlisted Company:</u> Founder of the Company named «Créer la Vitalité»